Legend Biotech (LEGN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.3B

Revenue (quarter)

$387.5M

Revenue growth (year over year)

+51.90%

Gross profit (trailing twelve months)

$719.3M

Gross margin

56.58%

Net income (trailing twelve months)

−$91.5M

Net income (quarter)

$33.2M

Net income growth (year over year)

+126.48%

Net margin

−7.20%

Return on equity

−8.08%

EPS (trailing twelve months)

−$0.50

Book value per share

$6.35

P/E (trailing twelve months)

—

Price to book

2.83

Debt to assets

29.77%

Payout ratio

—

Dividend yield

—

Company profile

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

• Is Legend Biotech (LEGN) profitable?

  No. Legend Biotech reported a net loss of $91.5M over the trailing twelve months.

• How much revenue does Legend Biotech (LEGN) make?

  Legend Biotech generated $1.3B in revenue over the trailing twelve months, up 51.90% year over year.

• How do I buy stock in Legend Biotech (LEGN)?

  LEGN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.